On 25 February, Acacia Research Corporation (NASDAQ:ACTG) posted its earnings results on Thursday. The company reported $0.09 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.11 by $0.02. The business had revenue of $37.50 million for the quarter, compared to analyst estimates of $27.61 million.
Acacia Research Corporation (NASDAQ:ACTG) belongs to Services sector. Its net profit margin is -51.60% and weekly performance is -21.78%. On last trading day company shares ended up at $2.98. Acacia Research Corporation (NASDAQ:ACTG) distance from 50-day simple moving average (SMA50) is -17.14%.
On 25 February, Universal Display Corp. (NASDAQ:OLED) reported Q4 EPS of $0.39, $0.12 worse than the analyst estimate of $0.51. Revenue for the quarter came in at $62.3 million versus the consensus estimate of $71.54 million.
Universal Display Corp. (NASDAQ:OLED) shares moved down -11.45% in last trading session and ended the day at $43.99. OLED Gross Margin is 63.80% and its return on assets is 1.90%. Universal Display Corp. (NASDAQ:OLED) quarterly performance is -9.24%.
DineEquity, Inc. (NYSE:DIN) said that, it will present J.P. Morgan Gaming, Lodging, Restaurant & Leisure Management Access Forum on Friday, March 11, 2016 from 10:40 a.m. to 11:10 a.m. Pacific Time in Las Vegas, Nevada
On 26 February, DineEquity, Inc. (NYSE:DIN) shares moved down -6.25% and were closed at $90.90. DIN EPS growth in last 5 year was 28.10%. DineEquity, Inc. (NYSE:DIN) year to date (YTD) performance is 7.36%.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will release its fourth quarter and year end 2015 financial results on Tuesday, March 1, 2016 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the fourth quarter and year end of 2015 at 10:00 a.m. Eastern Time on March 1, 2016.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) ended the last trading day at $9.07. Company weekly volatility is calculated as 6.11%. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) showed a weekly performance of -1.41%.
Equities researchers at Wunderlich began coverage on shares of Blackbaud, Inc. (NASDAQ:BLKB) in a research note issued to investors on Thursday, The Fly reports. The firm set a “buy” rating and a $69.00 price target on the stock. Wunderlich’s price objective points to a potential upside of 22.71% from the company’s previous close.
Blackbaud Inc. (NASDAQ:BLKB) shares increased 1.01% in last trading session and ended the day at $57.21. BLKB Gross Margin is 52.20% and its return on assets is 2.70%. Blackbaud Inc. (NASDAQ:BLKB) quarterly performance is -7.74%.